Evoke Pharma Inc. (NASDAQ:EVOK)’s share price reached a new 52-week high on Wednesday . The stock traded as high as $10.80 and last traded at $10.54, with a volume of 133,156 shares changing hands. The stock had previously closed at $10.39.

Several equities research analysts recently commented on EVOK shares. FBR & Co reissued a “buy” rating on shares of Evoke Pharma in a research note on Saturday, May 14th. Zacks Investment Research raised Evoke Pharma from a “hold” rating to a “buy” rating and set a $5.50 price target for the company in a research note on Tuesday, May 3rd. Brean Capital reissued a “buy” rating on shares of Evoke Pharma in a research note on Thursday, May 12th. Finally, Rodman & Renshaw reissued a “buy” rating on shares of Evoke Pharma in a research note on Thursday, May 12th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $17.47.

The company’s market capitalization is $75.73 million. The firm has a 50 day moving average of $6.63 and a 200-day moving average of $4.75.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.04. Equities research analysts predict that Evoke Pharma Inc. will post ($1.37) earnings per share for the current year.

In other Evoke Pharma news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of Evoke Pharma stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $4.70, for a total value of $1,617,364.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Parters Vii L. P. Domain sold 5,095 shares of Evoke Pharma stock in a transaction on Wednesday, April 27th. The shares were sold at an average price of $5.07, for a total value of $25,831.65. The disclosure for this sale can be found here.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.